From Dealroom · · 30s
VitriVax raises $87M for Lyme vaccine
VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine.
In brief
VitriVax secures $87 million Series C funding to develop first Lyme disease vaccine. VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists. Originally reported by Dealroom.
Funding round
VitriVax raised $87 million Series C to develop Lyme disease vaccine.
Market gap
No approved human Lyme vaccine exists, creating unmet need for new solution.
The bottom line
VitriVax raised $87 million Series C to pursue Lyme disease vaccine after no approved human vaccine exists.
Read the TL;DR — this story on one card.

